GB0708818D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0708818D0
GB0708818D0 GBGB0708818.0A GB0708818A GB0708818D0 GB 0708818 D0 GB0708818 D0 GB 0708818D0 GB 0708818 A GB0708818 A GB 0708818A GB 0708818 D0 GB0708818 D0 GB 0708818D0
Authority
GB
United Kingdom
Prior art keywords
alkyl
compounds
signifies
enantiomers
alkylcarbonylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0708818.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0708818(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Priority to GBGB0708818.0A priority Critical patent/GB0708818D0/en
Publication of GB0708818D0 publication Critical patent/GB0708818D0/en
Priority to AU2008246443A priority patent/AU2008246443B2/en
Priority to UAA200912720A priority patent/UA104844C2/uk
Priority to CN2008800151606A priority patent/CN101687858B/zh
Priority to KR1020097025071A priority patent/KR101598482B1/ko
Priority to NZ580962A priority patent/NZ580962A/en
Priority to DK08741778.8T priority patent/DK2155731T3/da
Priority to CA2686387A priority patent/CA2686387C/en
Priority to JP2010507348A priority patent/JP5559677B2/ja
Priority to SI200830191T priority patent/SI2155731T1/sl
Priority to ES08741778T priority patent/ES2360841T3/es
Priority to PCT/PT2008/000019 priority patent/WO2008136695A1/en
Priority to BRPI0811275A priority patent/BRPI0811275B8/pt
Priority to HK10109325.5A priority patent/HK1142898B/xx
Priority to PL08741778T priority patent/PL2155731T3/pl
Priority to RU2009145270/04A priority patent/RU2501796C2/ru
Priority to ARP080101912A priority patent/AR066457A1/es
Priority to US12/599,014 priority patent/US8481582B2/en
Priority to DE602008005141T priority patent/DE602008005141D1/de
Priority to AT08741778T priority patent/ATE499367T1/de
Priority to MX2009012041A priority patent/MX2009012041A/es
Priority to EP08741778A priority patent/EP2155731B1/en
Priority to HR20110253T priority patent/HRP20110253T1/hr
Priority to RS20110165A priority patent/RS51692B/sr
Priority to CL2008001321A priority patent/CL2008001321A1/es
Priority to TW097116854A priority patent/TWI458722B/zh
Priority to NO20093275A priority patent/NO20093275L/no
Priority to IL201921A priority patent/IL201921A/en
Priority to ZA2009/08612A priority patent/ZA200908612B/en
Priority to CY20111100414T priority patent/CY1111517T1/el
Priority to US13/917,385 priority patent/US9630951B2/en
Priority to US15/454,201 priority patent/US20170369478A1/en
Priority to ARP180102520A priority patent/AR112789A2/es
Priority to US16/402,454 priority patent/US20190322648A1/en
Priority to US17/315,791 priority patent/US20210261533A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0708818.0A 2007-05-08 2007-05-08 Compounds Ceased GB0708818D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
HR20110253T HRP20110253T1 (hr) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze
RS20110165A RS51692B (sr) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kao inhibitori dopamin-beta-hidroksilaze
RU2009145270/04A RU2501796C2 (ru) 2007-05-08 2008-05-06 Производные 1,3-дигидроимидазол-2-тиона в качестве ингибиторов дофамин-бета-гидроксилазы
DE602008005141T DE602008005141D1 (de) 2007-05-08 2008-05-06 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
CN2008800151606A CN101687858B (zh) 2007-05-08 2008-05-06 作为多巴胺-β-羟化酶抑制剂的1,3-二氢咪唑-2-硫酮衍生物
KR1020097025071A KR101598482B1 (ko) 2007-05-08 2008-05-06 도파민-베타-히드록실라아제의 저해제인 1,3-디히드로이미다졸-2-티온 유도체
NZ580962A NZ580962A (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
DK08741778.8T DK2155731T3 (da) 2007-05-08 2008-05-06 1,3-Dihydroimidazol-2-thion-derivater som inhibitorer af dopamin-beta-hydroxylase
CA2686387A CA2686387C (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
JP2010507348A JP5559677B2 (ja) 2007-05-08 2008-05-06 ドーパミン−β−ヒドロキシラーゼの阻害剤としての１，３−ジヒドロイミダゾール−２−チオン誘導体
SI200830191T SI2155731T1 (sl) 2007-05-08 2008-05-06 Derivati 1,3-dihidroimidazol-2-tiona kot inhibitorji dopamin-betahidroksilaze
ES08741778T ES2360841T3 (es) 2007-05-08 2008-05-06 Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
BRPI0811275A BRPI0811275B8 (pt) 2007-05-08 2008-05-06 derivado de 1,3-di-hidroimidazol-2-tiona como inibidor da dopamina-beta-hidroxilase, processo para a preparação do mesmo, composição farmacêutica, e, uso do mesmo
HK10109325.5A HK1142898B (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
PL08741778T PL2155731T3 (pl) 2007-05-08 2008-05-06 Pochodne 1,3-dihydroimidazolo-2-tionu jako inhibitory dopamino-beta-hydroksylazy
AU2008246443A AU2008246443B2 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
ARP080101912A AR066457A1 (es) 2007-05-08 2008-05-06 Derivados de imidazol, procesos de obtencion, composiciones farmaceuticas y usos.
US12/599,014 US8481582B2 (en) 2007-05-08 2008-05-06 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
UAA200912720A UA104844C2 (uk) 2007-05-08 2008-05-06 Похідні 1,3-дигідроімідазол-2-тіону як інгібітори дофамін-бета-гідроксилази
AT08741778T ATE499367T1 (de) 2007-05-08 2008-05-06 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
MX2009012041A MX2009012041A (es) 2007-05-08 2008-05-06 Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.
EP08741778A EP2155731B1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase
TW097116854A TWI458722B (zh) 2007-05-08 2008-05-07 多巴胺-β-羥化酶抑制劑，其製備方法，包含其之醫藥組合物及其用途
CL2008001321A CL2008001321A1 (es) 2007-05-08 2008-05-07 Compuestos derivados de (cromanil o tiocromanil o naftalenil)-1,3-dihidroimidazol-2-tiona, inhibodores de dopamina betahidroxilasa; procedimiento de preparacion de enantiomeros (r) y (s) separados o en mezcla; composicion farmaceutica; y su uso en el tratamiento de ansiedad, jaqueca, trastornos cardiovasculares, entre otros.
NO20093275A NO20093275L (no) 2007-05-08 2009-11-03 1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
IL201921A IL201921A (en) 2007-05-08 2009-11-04 History 1, 3-Dihydroimidazole-2-Theon as dopamine inhibitors-in-cell-hydroxylase
ZA2009/08612A ZA200908612B (en) 2007-05-08 2009-12-04 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
CY20111100414T CY1111517T1 (el) 2007-05-08 2011-04-26 Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης
US13/917,385 US9630951B2 (en) 2007-05-08 2013-06-13 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
US15/454,201 US20170369478A1 (en) 2007-05-08 2017-03-09 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
ARP180102520A AR112789A2 (es) 2007-05-08 2018-09-05 COMPUESTOS INHIBIDORES DE DOPAMINA-b-HIDROXILASA
US16/402,454 US20190322648A1 (en) 2007-05-08 2019-05-03 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase
US17/315,791 US20210261533A1 (en) 2007-05-08 2021-05-10 1,3-dihydroimidazole-2-thione derivatives as inhibitors of dopamine-beta-hydroxylase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds

Publications (1)

Publication Number Publication Date
GB0708818D0 true GB0708818D0 (en) 2007-06-13

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0708818.0A Ceased GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds

Country Status (29)

Country Link
US (5) US8481582B2 (enExample)
EP (1) EP2155731B1 (enExample)
JP (1) JP5559677B2 (enExample)
KR (1) KR101598482B1 (enExample)
CN (1) CN101687858B (enExample)
AR (2) AR066457A1 (enExample)
AT (1) ATE499367T1 (enExample)
AU (1) AU2008246443B2 (enExample)
BR (1) BRPI0811275B8 (enExample)
CA (1) CA2686387C (enExample)
CL (1) CL2008001321A1 (enExample)
CY (1) CY1111517T1 (enExample)
DE (1) DE602008005141D1 (enExample)
DK (1) DK2155731T3 (enExample)
ES (1) ES2360841T3 (enExample)
GB (1) GB0708818D0 (enExample)
HR (1) HRP20110253T1 (enExample)
IL (1) IL201921A (enExample)
MX (1) MX2009012041A (enExample)
NO (1) NO20093275L (enExample)
NZ (1) NZ580962A (enExample)
PL (1) PL2155731T3 (enExample)
RS (1) RS51692B (enExample)
RU (1) RU2501796C2 (enExample)
SI (1) SI2155731T1 (enExample)
TW (1) TWI458722B (enExample)
UA (1) UA104844C2 (enExample)
WO (1) WO2008136695A1 (enExample)
ZA (1) ZA200908612B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
KR101941467B1 (ko) * 2010-12-22 2019-01-23 바이알 - 포르텔라 앤드 씨에이 에스에이 결정형 및 이들의 제조방법
PT2726454T (pt) * 2011-06-29 2018-05-07 Bial Portela & Ca Sa Processo
TR201815850T4 (tr) * 2012-11-14 2018-11-21 Bial Portela & Ca Sa Pulmoner arteryel hipertansiyonun ve akciğer hasarının tedavisinde kullanım için 1,3-dihidroimidazol-2-tion türevleri.
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
PE20200924A1 (es) 2017-09-13 2020-09-14 Amgen Inc Compuestos de bisamida sustituida que activan el sarcomero cardiaco
CA3082337A1 (en) * 2017-12-04 2019-06-13 Bial - Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
MA54225A (fr) * 2018-11-12 2021-09-22 Immunogen Inc Procédés de préparation de dérivés de benzodiazépine cytotoxiques
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors
JP2024503906A (ja) * 2021-01-26 2024-01-29 江▲蘇▼▲亞▼虹医▲薬▼科技股▲フン▼有限公司 経路調節因子、それを有する医薬組成物、その使用、及びそれを使用する治療方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
RU2145321C1 (ru) * 1994-04-26 2000-02-10 Синтекс (Ю.Эс.Эй) Инк. Производные бензоциклоалкилазолотиона
AR032711A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
ES2360841T3 (es) 2011-06-09
DK2155731T3 (da) 2011-05-02
CA2686387C (en) 2015-06-30
PL2155731T3 (pl) 2011-07-29
RS51692B (sr) 2011-10-31
US9630951B2 (en) 2017-04-25
HK1142898A1 (en) 2010-12-17
JP2010526136A (ja) 2010-07-29
EP2155731A1 (en) 2010-02-24
US20100137390A1 (en) 2010-06-03
US20130345275A1 (en) 2013-12-26
RU2501796C2 (ru) 2013-12-20
SI2155731T1 (sl) 2011-05-31
JP5559677B2 (ja) 2014-07-23
NZ580962A (en) 2012-05-25
IL201921A0 (en) 2010-06-16
US8481582B2 (en) 2013-07-09
IL201921A (en) 2013-11-28
NO20093275L (no) 2010-02-04
EP2155731B1 (en) 2011-02-23
CN101687858A (zh) 2010-03-31
TWI458722B (zh) 2014-11-01
AU2008246443A1 (en) 2008-11-13
CY1111517T1 (el) 2015-08-05
HRP20110253T1 (hr) 2011-05-31
MX2009012041A (es) 2010-02-18
AR112789A2 (es) 2019-12-11
AR066457A1 (es) 2009-08-19
BRPI0811275A2 (pt) 2014-12-23
BRPI0811275B8 (pt) 2021-05-25
CL2008001321A1 (es) 2008-12-26
US20210261533A1 (en) 2021-08-26
AU2008246443A8 (en) 2010-01-07
US20170369478A1 (en) 2017-12-28
KR20100017546A (ko) 2010-02-16
ZA200908612B (en) 2010-11-24
RU2009145270A (ru) 2011-06-20
WO2008136695A1 (en) 2008-11-13
CN101687858B (zh) 2012-12-26
ATE499367T1 (de) 2011-03-15
BRPI0811275B1 (pt) 2020-01-07
AU2008246443B2 (en) 2013-07-11
DE602008005141D1 (de) 2011-04-07
CA2686387A1 (en) 2008-11-13
TW200918525A (en) 2009-05-01
UA104844C2 (uk) 2014-03-25
US20190322648A1 (en) 2019-10-24
KR101598482B1 (ko) 2016-02-29

Similar Documents

Publication Publication Date Title
GB0708818D0 (en) Compounds
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
ATE451373T1 (de) N-aryl diazaspirozyklische verbindungen, deren verwendung und das verfahren zu ihren herstellung
NO20083710L (no) Dihydrotienopyrimidin for behandling av betennelsesforstyrrelser
MY141229A (en) Piperidine-benzenesulfonamide derivatives
MXPA04009784A (es) Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas.
EP2423207A3 (en) 2-(cyclic amino)-pyrimidone derivatives as TPK1 inhibitors
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
WO2009011285A1 (ja) ヘテロアリールベンゼン化合物
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY151072A (en) Heteroaryl derivative
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
MX2009009384A (es) Malonamidas como antagonistas de orexina.
WO2008157404A3 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MY143578A (en) Piperazinediones as oxytocin receptor antagonists
EA200501148A1 (ru) Пиридилоксиметильные и бензизоксазольные азабициклические производные
NO20074617L (no) Nye forbindelser for behandling av inflamotoriske sykdommer
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists
MX355422B (es) Derivados de 1,3-dihidroimidazol-2-tiona para el uso en el tratamiento de hipertension arterial pulmonar y daño pulmonar.
RU2008110945A (ru) N-оксиды как пролекарства производных пиперазина и пиперидина
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
EA200970046A1 (ru) Аминопроизводные в-гомоандростанов и в-гетероандростанов
DE502005003310D1 (de) Cycloalkyl substituierte 7-amino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200637552A (en) Macrocyclic analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2009148291A3 (en) 3- or 4-substituted piperidine compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)